NEUROCRINE BIOSCIENCES INC (NBIX) Return on equity 2016–2025
NEUROCRINE BIOSCIENCES INC (NBIX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
14.7%FY2025 · since FY2016: -44.8% → 14.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 14.7% | +1.5 pp |
| FY2024 | 13.2% | +2.0 pp |
| FY2023 | 11.2% | +2.1 pp |
| FY2022 | 9.0% | +2.5 pp |
| FY2021 | 6.5% | -29.6 pp |
| FY2020 | 36.2% | +30.4 pp |
| FY2019 | 5.8% | +1.4 pp |
| FY2018 | 4.4% | +42.7 pp |
| FY2017 | -38.3% | +6.5 pp |
| FY2016 | -44.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More NBIX financial trends
NBIX RevenueNBIX Net incomeNBIX Net marginNBIX Gross profitNBIX Gross marginNBIX Operating incomeNBIX Operating marginNBIX Operating cash flowNBIX Free cash flowNBIX Capital expendituresNBIX Stock buybacksNBIX Dividends paidNBIX Total assetsNBIX Total liabilitiesNBIX Shareholders’ equityNBIX overview →